TABLE 2.
In vitro activity of HDACI against class I and class II HDAC isoforms
| HDAC isoform | IC50 against HDAC isoforms (nm) |
|||||
|---|---|---|---|---|---|---|
| Apicidin | Oxamflatin | Scriptaid | SAHA | Droxinostat | Valproic acid | |
| Class I | ||||||
| HDAC1 | 0.30 ± 0.15a1 | 3.96 ± 0.87 | 0.64 ± 0.09 | 13.7 ± 0.15 | 63,000 | 171,000 |
| HDAC2 | 1.2 ± 0.80 | 0.16 ± 0.11 | 1.4 ± 0.74 | 62.0 ± 0.15 | 250,000 | 634,000 |
| HDAC3 | 0.98 ± 0.22 | 10.3 ± 1.2 | 607 ± 93 | 869 ± 0.15 | 2000 | 5,500,000 |
| HDAC8 | 0.26 ± 0.09 | 0.37 ± 0.15 | 14.5 ± 1.1 | 6.8 ± 0.15 | 5000 | 756,000 |
| Class II | ||||||
| HDAC4 | >50,000 | 3800 ± 1100 | 14,000 ± 1500 | >50,000 | NDb | ND |
| HDAC5 | >50,000 | >50,000 | >50,000 | >50,000 | ND | ND |
| HDAC6 | >50,000 | 390 ± 73 | 34 ± 9 | 5500 ± 760 | ND | ND |
| HDAC7 | >50,000 | 840 ± 39 | 2200 ± 350 | >50,000 | ND | ND |
| HDAC9 | >50,000 | >50,000 | >50,000 | >50,000 | ND | ND |
a Data represent the mean ± S.D. from three replicate experiments.
b ND, not determined.